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An-wen Liu3* and Quentin Liu1,2*Abstract
Background: Platinum-based chemotherapy improves survival among patients with non-small cell lung cancer
(NSCLC), but the efficiency is limited due to resistance. In this study, we aimed to identify the expression of
Aurora-A and its correlation with cisplatin resistance and prognosis in NSCLC.
Methods: We used immunohistochemical analysis to determine the expression of Aurora-A protein in 102 NSCLC
patients treated by surgery and adjuvant cisplatin-based chemotherapy. The prognostic significances were assessed
by Kaplan-Meier survival estimates and Cox models. The potential role of Aurora-A in the regulation of cisplatin
resistance in NSCLC cells was examined by transfections using expression vector and small interfering RNA or using
small-molecule inhibitors.
Results: Aurora-A expression was significantly associated with clinical stage (p = 0.018), lymph node metastasis
(p = 0.038) and recurrence (p = 0.005), and was an independent prognostic parameter in multivariate analysis. High
level of Aurora-A expression predicted poorer overall survival (OS) and progression-free survival (PFS). In vitro data
showed that Aurora-A expression was elevated in cisplatin-resistant lung cancer cells, and overexpression or
knockdown of Aurora-A resulted in increased or decreased cellular resistance to cisplatin. Furthermore, inhibition of
Aurora-A reversed the migration ability of cisplatin-resistant cells.
Conclusions: The current findings suggest that high Aurora-A expression is correlated with cisplatin-based
chemotherapeutic resistance and predicts poor patient survival in NSCLC. Aurora-A might serve as a predictive
biomarker of drug response and therapeutic target to reverse chemotherapy resistance.
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Lung cancer is the leading cause of cancer mortality
worldwide [1]. Non-small cell lung cancer (NSCLC) ac-
counts for approximately 85% of lung cancers, including
squamous cell carcinoma, adenocarcinoma and large cell
carcinoma [2]. The overall survival for NSCLC remains* Correspondence: wsw_2003@163.com; awliu666@163.com;
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unless otherwise stated.poor, with 5-year survival rates only 10–20% [3]. Cur-
rently, surgery represents the main curative treatment
modality for cure of NSCLC. Additional therapy is
necessary because of high rates of distant and local dis-
ease recurrence after surgical resection. Platinum-based
chemotherapy (cisplatin or carboplatin in combination
with navelbine, gemcitabine, or paclitaxel) has been
widely used as first-line regimen for advanced NSCLC.
However, NSCLC patients frequently exhibit resistance
to chemotherapy [4,5]. Previous studies have revealed
that the major resistance mechanisms include reduced
uptake and/or increased efflux, enhanced DNA repair,
and failure of cell-death pathways, metastatic tumor [6].
In addition, several studies have reported multiple geneticThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Xu et al. Journal of Translational Medicine 2014, 12:200 Page 2 of 14
http://www.translational-medicine.com/content/12/1/200aberrations that might predict cisplatin sensitivity in
NSCLC patients, such as ERCC1, BRCA1, XRCC1 and
CFL1 [7-9]. However, much work remains to be done to
validate the clinical relevance of resistance genes to
benefit from adjuvant platinum-based chemotherapy.
Aurora-A (also called STK15/BTAK) is a member of
serine/threonine kinase family. It is involved in various
mitotic events, such as centrosome maturation and sep-
aration, mitotic entry, bipolar-spindle assembly, chromo-
some alignment on the metaphase plate and cytokinesis.
In human cells, Aurora-A expression and kinase activity
are increased during late G2 to M phase, and its subcel-
lular localization dynamically changes during the cell
cycle [10]. The levels of Aurora-A mRNA and protein
are increased in various malignant tumors including colon,
breast, bladder, ovarian and pancreatic cancers, indicating
that it is important for tumor formation or progression
[11-14]. Furthermore, we and others have previously
showed that overexpression of Aurora-A increases migra-
tion and leads to resistance to chemotherapy drugs
[15-18]. Accordingly, Aurora-A serves as a promising tar-
get in cancer therapy, and several small-molecule inhibi-
tors for Aurora-A kinase are currently being investigated
within clinical trials [19]. The novel Aurora-A kinase in-
hibitor alisertib (MLN8237) is currently undergoing evalu-
ation in a phase I/II trial with paclitaxel in recurrent
ovarian cancer [20]. The inhibitor alisertib seems clinically
active in both B- and T-cell aggressive lymphomas, and
confirmatory single-agent and combination studies have
been initiated [21].
In the present study, we detected the expression of
Aurora-A in NSCLC patients treated with adjuvant
cisplatin-based therapy and determined its correlation
with clinical characteristics. We also validated an associ-
ation between elevated Aurora-A expression and cisplatin
resistance in vitro. In addition, we investigated the effect
of Aurora-A on the sensitivity of cisplatin in A549 and
H460 human lung cancer cells.
Methods
Patients and clinical specimens
The present study included 102 patients with NSCLC,
diagnosed at the Cancer Center, Sun Yat-sen University
between 2002 and 2003. The patients, 70 males (69%)
and 32 females (31%), ranged in age from 38 to 75 years
(mean 60 years). Histological examination was per-
formed on formalin-fixed tissues in all cases and tumors
were diagnosed and classified according to the AJCC
(American Joint Committee on Cancer guidelines) clas-
sification [22].
All the patients (from stage I to stage III) underwent
radical surgery of primary tumor and lymph nodes, and
received adjuvant cisplatin-based chemotherapy after sur-
gery. No chemotherapy or radiotherapy was given topatients before surgery. Written informed consent for the
use of the tissues was obtained from all patients before
surgery, and the study was approved by the Institute
Research Ethics Committee of Sun Yat-sen University.Cell lines and cell culture
The human lung adenocarcinoma cell lines A549 and
A549/DDP (cisplatin-resistant variant) were graciously
provided by Dr. Xiaofeng Zhu, Sun Yat-sen University
[23]. The lung cancer cell lines NCI-H460 (H460) and
H460/DDP (cisplatin-resistant variant) were graciously
provided by Dr. Liwu Fu, Sun Yat-sen University [24].
Both cell lines were cultured in RPMI-1640 supplemented
with 10% fetal bovine serum at 37°C in humidified 5%
CO2 incubator. The A549/DDP and H460/DDP cells were
cultured with 6 μM cisplatin (Sigma–Aldrich, St.Louis,
MO) to maintain drug resistance.Transient transfection
Cells were transfected with an empty vector pCS2+ or
pCS2 + −Aurora-A (a gift from Joan Ruderman, Harvard
Medical School, Boston, MA), or interfering RNA
(siRNA) and negative control using Lipofectamine 2000
as described earlier [17]. The negative control (NC)
siRNA and siRNA against Aurora-A (5′-AUGCCCUGU
CUUACUGUCA-3′) were synthesized by GenePharma
Company (Shanghai).Lentiviral transfection for stable expression cells
Plasmid pLVX-DsRed-N1-Monomer (Clontech) express-
ing Aurora-A was from Dr. Feimeng Zheng, Sun Yat-sen
University. The shRNA sequences against GFP (Sence-
5′-GCAAGCTGACCCTGAAGTTCAT, Antisense-5′-
ATGAACTTCAGGGTCAGCTTGC) and Aurora-A (Sence-
5′-CACATACCAAGAGACCTACAA, Antisense-5′-TTG
TAGGTCTCTTGGTATGTG) were cloned into pLKO-
Tet-On (Addgene). Lentiviruse was produced in 293Tcells
as described earlier [25].Cell viability assay
The MTT assay was used to assess cell viability. 5,000
cells were plated in 96-well plates and then were exposed
to various concentrations of cisplatin, VX-680 (Kava Tech-
nology), MLN8237 (Selleck Chemicals) or combinations.
Following treatment, 0.5 mg/ml MTT (Sigma–Aldrich)
solution was added to each well, and incubated for 4 hours
(h). After the incubation, culture media was discarded
followed by addition of 0.15 ml DMSO and vibration for
10 minutes (min). The absorbance at 570 nm was deter-
mined. The cell inhibition ratio was calculated as a frac-
tion of the untreated controls.
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5,000 cells were seeded into six-well plates in triplicate
and incubated for 8–10 days. Colonies were stained with
crystal violet and counted.
Western blot analysis
Cells were lysed with the RIPA buffer on ice before be-
ing subjected to western blot analysis. The protein con-
centration was detected by the Bradford method. Total
proteins were fractionated using SDS-PAGE and trans-
ferred onto nitrocellulose membrane. The membrane was
blocked and incubated with mouse anti-GAPDH antibodyFigure 1 Representative specimens of Aurora-A expression are shown
(A) Non-neoplastic lung tissues showed nearly negative expression of Auro
NSCLC patient sample (100×). (C) High-intensity Aurora-A expression was s
higher magnification (200×) from the area of the box in (A), (B), (C) respec(Ambion Biotechnology), rabbit anti-Aurora-A antibody
(Upstate), rabbit anti-p-Aurora-A antibody (Thr288, Cell
Signaling), rabbit anti-histone H3 antibody (Epitomics),
and rabbit anti-p-histone H3 antibody (Ser10, SAB).
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde at room
temperature for 15 min and permeabilized in 0.25% Tri-
ton X-100 in PBS for 10 min, and incubated in 3% BSA
blocking solution for 30 min. The cells were incubated
with anti-Aurora-A (Upstate) and α-tubulin (Sigma) anti-
bodies for 1 h. The immune complexes were detected within tissue microarrays by immunohistochemistry analysis.
ra-A (100×). (B) Low-intensity Aurora-A expression was shown in a
hown in another NSCLC case (100×). (A’), (B’), (C’) demonstrated the
tively.
Table 1 Association of Aurora-A expression with patient’s
clinicopathologic characteristics in NSCLC
Aurora-A
Variable All cases High Low P
Age (years)
≥ 60.0 36 20 16
< 60.0 66 37 29 0.961
Gender
Male 70 35 35
Female 32 22 10 0.077
Smoking history
Yes 57 30 27
No 45 27 18 0.457
CEA (ng/ml)
> 5.0 52 32 20
≤ 5.0 50 25 25 0.241
Initial clinical stage
I 11 5 6
II 24 8 16 0.018
III 67 44 23
Histology
Squamous cell carcinoma 12 7 5
Adenocarcinoma 88 48 40 0.433
Adenosquamous cell carcinomas 2 2 0
Differentiation
Highly 15 6 9
Modrately 33 17 16 0.236
Poorly 54 34 20
Tumor stage
T1 + T2 63 34 29
T3 + T4 39 23 16 0.621
Lymph node metastasis
Negative 26 10 16
Positive 76 47 29 0.038
Recurrence
Local 35 15 20
Distance 46 36 10 0.005
Negative 21 6 15
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rabbit conjugated to Alexa-546 secondary antibody (Mo-
lecular Probes). Nucleus was stained with DAPI.
Flow cytometry
Apoptosis analysis was conducted with an Annexin V-
FITC Apoptosis Detection Kit (KeyGen Biotech) accord-
ing to the manufacturer’s protocol. The percentage of
apoptotic cells was determined using FACS flow cyt-
ometer equipped software (BECKMAN).
Wound healing assay
Cells transfected with RNAi or not were seeded in 24-
well plates and grown until 70-80% confluence. The cells
were then serum starved for 24 h. A linear wound was
created using a pipette tip and observed and photo-
graphed at various times as indicated in the figure legends.
Immunohistochemistry analysis and evaluation
Formalin-fixed, paraffin-embedded samples were cut in
4 μm sections and mounted on slides. Slides were deparaf-
finized, rehydrated, and treated with 3% H2O2 in methanol
for 15 min to inhibit endogenous peroxidase. Pretreat-
ment was done in microwave with Tris/EDTA buffer solu-
tion (pH 8.0). After transfer to a humidified chamber, the
slides were blocked with 10% normal goat serum at room
temperature for 30 min and incubated with mouse anti-
Aurora-A monoclonal antibody (Sigma, A1231, 1:200
dilution). Detection of the primary antibody was done
using the Envision DAKO EnVision Detection kit, (3, 3-
diaminobenzidine; code K 5007, DAKO Cytomation,
Glostrup, Denmark) according to the protocol of the
manufacturer. Finally, samples were counterstained with
hematoxylin, dehydrated, and mounted. The positive
control sample was a normal colonic mucosa section
known to express Aurora-A. The negative control was
obtained by replacing the primary antibody with a nor-
mal murine IgG.
Each case was rated according to a score that added a
scale of intensity of staining to the area of staining. At least
10 high-power fields were chosen randomly, and >1,000
cells were counted for each section. The intensity of stain-
ing was graded on the following scale: 0, no staining; 1,
weak; 2, moderate; 3, strong. The area of staining was eval-
uated as follows: 0, no staining of cells in any microscopic
fields; 1+, <30% of tissue stained positive; 2+, between 30%
and 60% stained positive; 3+, >60% stained positive [26].
The minimum score when summed (extension + intensity)
was therefore, 0, and the maximum. Two independent pa-
thologists (W.H.Z. and J.X.), blind to follow-up data, were
responsible for IHC staining evaluation. A third patholo-
gist arbitrated when any discrepancy arose between these
two pathologists.Selection of cutoff score for Aurora-A expression
Receiver operating characteristic (ROC) curve analysis
was carried out to select Aurora-A cutoff score [27,28].
In brief, at each immunohistochemical score, the sensi-
tivity and specificity for the outcome under study was
plotted, generating an ROC curve. The score localized
closest to the point at both maximizing sensitivity and
specificity, the point (0.0, 1.0) on the curve, was selected
as the cutoff score above which Aurora-A expression
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the survival features were dichotomized: survival (death
VS. others (censored, alive or death from other causes)).
Follow up
All patients had follow-up records for over 5 years. After
the completion of therapy, patients were observed at
3 month intervals during the first 3 years and at 6 month
intervals thereafter. OS was defined as the time from
diagnosis to the date of death or when censored at the
latest date if patients were still alive. PFS was assessed
from the first day of treatment to the earliest signs of
disease progression as determined by CT or MRI imaging
using RECIST (Response Evaluation Criteria In Solid Tu-
mors) criteria, or death from any cause.
Statistical analysis
Optimal cutpoint for Aurora-A expression was obtained
by ROC analysis. The chi-square test or Fisher’s exact test
was used to estimate the correlation between Aurora-A
expression and clinic pathological variables. Univariate
survival analysis for Aurora-A was carried out using the
Kaplan-Meier method, and the differences in survival
probabilities were evaluated by the log-rant test. The
hazard ratios and 95% confidence intervals for patient
outcome were determined using the multivariate Cox
proportional hazards model. Statistical analysis was per-
formed using SPSS v. 17.0 (SPSS, Inc, Chicago, IL).
Two-sided P values < 0.05 were considered statistically
significant. Experiments were repeated at least threeFigure 2 Kaplan-Meier survival analysis of Aurora-A expression in NSC
correlated with poor overall survival, (B) and progression-free survival. The
expression of Aurora-A was 27.25 vs. 72.2 months (p < 0.001) and 15.5 vs. 5times. Data were mean ± SD. Differences among variables
were evaluated by ANOVA, two-tailed Student’s t-tests.
P values < 0.05 were considered to be significant.
Results
Aurora-A expression in NSCLC tissues
The specificity for antibody targeting Aurora-A was
showed in Additional file 1: Figure S1 by western blot
analysis. The staining of Aurora-A was nearly negative
(Figure 1A and A’) in adjacent non-neoplastic lung tis-
sues, whereas NSCLC tissues showed elevated expres-
sion of Aurora-A (Figure 1B and C). Aurora-A staining
located in both nucleus and cytoplasm, predominantly in
nucleus (Figure 1B’ and C’). To select a relevant immuno-
histochemical cutoff score to describe Aurora-A overex-
pression in NSCLC, receiver operating characteristic
(ROC) curve analysis was carried out. As shown in
Additional file 1: Figure S2, the Aurora-A cutoff scores for
OS and PFS were 3.4 (p = 0.004) and 3.2 (p = 0.014) re-
spectively. We thus divided the cohort into high (score ≥ 4)
and low (score < 4) populations based on the cutoff points.
Aurora-A expression and clinicopathological
characteristics
Clinicopathological features were listed in Table 1 in re-
lation to Aurora-A expression status. High expression of
Aurora-A was detected in 57 out of 102 (55.9%) selected
NSCLC tissues and low in other 45 (44.1%) cases. In
high-Aurora-A expression group, the incidence of cases
in stage III was statistically significantly higher than inLC patients. (A) High expression of Aurora-A (Aur-A) was closely
median duration of overall survival for patients with high and low
7.5 months (p < 0.001), respectively.
Figure 3 (See legend on next page.)
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Figure 3 Kaplan-Meier survival analysis of Aurora-A expression in subsets of NSCLC patients with different stage. (A) Probability of
overall survival and (B) progression-free survival of NSCLC patients with stage I in the testing set: low expression, n = 6; high expression, n = 5.
(C) Probability of overall survival and (D) progression-free survival of NSCLC patients with stage II in the testing set: low expression, n = 16; high
expression, n = 8. (E) Probability of overall survival and (F) progression-free survival of NSCLC patients with stage III in the testing set: low
expression, n = 23; high expression, n = 44.
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spectively; p = 0.006). Further correlation analysis demon-
strated that high Aurora-A expression was significantly
associated with clinical stage (p = 0.018), lymph node me-
tastasis (p = 0.038) and recurrence (p = 0.005). Regarding
other clinicopathological variables, there was no statisti-
cally significant correlation observed in age, gender, smok-
ing history, carcino-embryonic antigen (CEA), histology,
differentiation and tumor stage.Aurora-A expression and survival
The Kaplan–Meier analysis indicated that the overall sur-
vival (OS) of patients with high Aurora-A expression was
significantly poorer than those with low Aurora-A expres-
sion (the median duration of OS 27.25 vs. 72.2 months,
respectively, p < 0.001; Figure 2A). Also, elevated expres-
sion of Aurora-A predicted an inferior progression-freeTable 2 Results of univariate and multivariate Cox proportion
Variable Univaria
Hazard ratio 95%
Age (years) ≥ 60.00 (VS. < 60.0) 1.186 (0.
Gender Male (VS. Female) 1.249 (0.
Smoking history Yes (VS. No) 1.504 (0.






Squamous cell carcinoma 1.898 (0.2
Adenocarcinoma 2.191 (0.2





Tumor stage T4 + T3 (VS. T2 + T1) 1.534 (0.
Lymph node metastasis Positive (VS. Negative) 2.460 (1.
Aurora-A High (VS. Low) 2.971 (1.survival (PFS) with the median duration of PFS 15.5 vs.
57.5 months respectively (p < 0.001, Figure 2B).
Further analysis was performed between Aurora-A ex-
pression and subsets of NSCLC patients with each clin-
ical stage. High expression of Aurora-A associated with
a significant trend toward worse OS and PFS in patients
of stage I (p = 0.032 for OS and p = 0.007 for PFS,
Figure 3A and B), stage II (p = 0.026 for OS and p =
0.038 for PFS, Figure 3C and D), and stage III (p = 0.017
for OS and p = 0.002 for PFS, Figure 3E and F).Multivariate Cox regression analysis
Multivariate analysis using the Cox proportional hazards
model revealed that high Aurora-A expression was an
independent and significant prognostic factor for OS
(hazard ratio: 3.311; 95%CI: 1.899-5.775; p < 0.001;
Table 2) and PFS (hazard ratio: 3.360; 95%CI: 2.066-al-hazards analysis in the overall patient for death
For death
te analysis Multivariate analysis
confidence
interval
P Hazard ratio 95% confidence
interval
P
734 to 1.916) 0.487 1.016 (0.603 to 1.712) 0.952
752 to 2.074) 0.391 1.057 (0.451 to 2.477) 0.899
941 to 2.406) 0.088 1.520 (0.930 to 2.458) 0.095
288 to 3.326) 0.003 2.034 (1.223 to 3.385) 0.006
058 to 0.601) 0.005 0.281 (0.086 to 0.917) 0.035
248 to 0.812) 0.008 0.724 (0.384 to 1.364) 0.317
1 1 1
63 to 13.700) 0.525 5.540 (0.749 to 40.949) 0.093
77 to 17.325) 0.457 5.725 (0.688 to 47.634) 0.107
1 1 1
281 to 1.200) 0.142 1.138 (0.514 to 2.521) 0.750
479 to 1.322) 0.377 0.993 (0.562 to 1.757) 0.982
1 1 1
962 to 2.445) 0.072 1.295 (0.752 to 2.230) 0.352
319 to 4.588) 0.005 1.484 (0.519 to 4.247) 0.462
803 to 4.895) 0.000 3.311 (1.899 to 5.775) 0.000
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parameters, CEA level was evaluated as a positive in-
dependent prognostic factor for OS and PFS, tumor
size for PFS.
Overexpression of Aurora-A increases cellular resistance
to cisplatin
Since high level of Aurora-A was correlated with poor
prognosis in NSCLC patients that treated by platinum-
based chemotherapy, we sought to explore the association
between Aurora-A expression and cisplatin-resistance
in vitro. We detected the protein expression level ofFigure 4 Aurora-A overexpression correlates with cisplatin resistance
A549/DDP cells or in H460 and H460/DDP cells by western blotting. Equal
of Aurora-A by Immunofluorescence in A549 and A549/DDP cells. Red: Aur
transfected with an expression vector for Aurora-A or control (vector) and
indicated concentrations of DDP for 24 h and subjected to MTT assay (righ
lentivirus-mediated gene transfer. Two days after transfection, cells were se
blotting analysis and subjected to colony formation assay with incubation
Student’s t-tests.Aurora-A in A549 and drug-resistant A549/DDP cells by
Western blot and immunofluorescence analysis. As shown
in Figure 4A (upper panel) and B, Aurora-A expression
was elevated in cisplatin-resistant A549/DDP cells. A549/
DDP cells with higher Aurora-A level also showed raised
proliferation (Additional file 1: Figure S3). In another lung
cancer drug-resistant cell line H460/DDP, Aurora-A ex-
pression was elevated relative to H460 cells (Figure 4A,
lower panel). Then we performed forced expression of
Aurora-A in A549 and H460 cells (Figure 4C), and
treated the cells with increasing concentrations of cis-
platin. Forced expression of Aurora-A increased thein vitro. (A) Protein level of Aurora-A was detected in A549 and
loading of protein was determined by GAPDH. (B) The staining
ora-A; Green: Tubulin; Blue: DAPI. (C) A549 and H460 cells were
detected by western blotting (left panel). Cells were treated with
t panel). (D) Aurora-A was overexpressed in A549 cells through
lected by using 2 μg/ml puromycin. Cells were harvested for western
of DDP (2, 5 μM) or vehicle (0 μM) (n = 3), **p < 0.01, two-tailed
Figure 5 (See legend on next page.)
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Figure 5 Inhibition of Aurora-A reduces cellular resistance to cisplatin. (A) A549/DDP and H460/DDP cells were transfected with negative
control (NC) or Aurora-A siRNA for 48 h and subjected to western blotting (left panel). RNAi-treated cells were incubated with indicated
concentrations of DDP for 24 h, and were harvested for MTT assays (right panel). (B) A549/DDP cells expressing Aurora-A shRNA or GFP shRNA
(control) under Tet-inducible system were treated cells with doxycycline (Dox, 1 μg/ml) for 48 h and harvested for western blotting analysis. Cells
were subjected to colony formation assay in the presence of Dox (1 μg/ml) and DDP (0, 2, 5 μM) (n = 3), **p < 0.01, two-tailed Student’s t-tests.
(C) A549/DDP cells treated with increasing doses of VX-680, MLN8237or DMSO (control) for 24 h were lysed and subjected to western blotting.
(D) A549/DDP cells were treated with DDP or VX-680, or DDP in combination with VX-680 at the indicated concentrations for 24 h, and cellular
viability was assessed by MTT assay (upper panel). A549/DDP cells were treated with DDP or MLN8237, or DDP in combination with MLN8237
for 24 h, and then incubated in fresh medium for another 24 h and subjected to MTT assay (lower panel). (E) A549/DDP cells with indicated
treatment for 24 h were subjected to annexin V-FITC and PI staining. Data were mean ± SD (n = 3).
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bility assay. Colony formation assay indicated that over-
expression of Aurora-A enhanced cell growth and
resistance to cisplatin in A549 cells (Figure 4D).
Inhibition of Aurora-A reduces cellular resistance to
cisplatin
We knocked down Aurora-A expression in A549/DDP
and H460/DDP cells by siRNA (Figure 5A, left panel),
and found that it resulted in a significantly enhanced
sensitivity to cisplatin (Figure 5A, right panel). Colony for-
mation assays showed that down-regulation of Aurora-A
by Tet-inducible RNAi suppressed proliferation of A549/
DDP cells severely in the presence of cisplatin (Figure 5B).
We then used VX-680, a small-molecule inhibitor of the
Aurora kinases, and Aurora-A kinase specific inhibitor
MLN8237 to determine whether inhibition of Aurora-A
activity would induce the similar effect. As expected, incu-
bation of A549/DDP cells with increasing doses of VX-680
or MLN8237 led to decrease in Aurora-A phosphorylation
at Thr288 (Figure 5C). Phosphorylation inhibition was also
observed in histone H3 at Ser10 (Additional file 1: Figure
S4). A549/DDP and H460/DDP cells were treated with
single-agent DDP, VX-680, MLN8237, or DDP in combin-
ation with VX-680 or MLN8237. The results showed that
the cytotoxicity effect of DDP, VX-680 or MLN8237 was
not obvious, while combination of DDP and VX-680 or
combination of DDP and MLN8237 produced signifi-
cant higher cytotoxicity effects (Figure 5D; Additional
file 1: Figure S5). We also assessed apoptotic cell death
by annexin V-FITC staining. The combination treat-
ment induced higher proportion of apoptosis, compared
with single-agent treatment (Figure 5E).
Inhibition of Aurora-A reverses migration ability of
cisplatin-resistant cells
Given the association between Aurora-A expression levels
and metastasis in NSCLC patients, we sought to identify
whether inhibition of Aurora-A could reverse migration
ability of cisplatin-resistant cells. We employed wound-
healing assay to evaluate the effect of repression of Aurora-A on cell migration. As shown in Figure 6A, with DDP
treatment, the migration ability of A549/DDP cells was ob-
viously higher than A549 cells, and which was effectively
inhibited by lack of Aurora-A expression. Similar results
were observed by using Aurora kinase inhibitor VX-680 or
MLN8237 (Figure 6B).
Discussion
Platinum-based chemotherapy is commonly employed
for the treatment of NSCLC. Cisplatin exerts its antican-
cer effect via the induction of mitochondrial apoptosis
as a result of lethal DNA damage. Despite a consistent
rate of initial responses, cisplatin treatment often results
in the development of chemoresistance and numerous
mechanisms contribute to cisplatin resistance. In this
study, our data indicated that Aurora-A overexpression
was associated with poor survival in NSCLC patients
treated with cisplatin-based chemotherapy. Aurora-A
overexpression decreased the sensitivity of lung cancer
cells to cisplatin in vitro, and Aurora-A inhibition en-
hanced cisplatin-induced apoptosis. Additionally, Aurora-
A promotes the migration in cisplatin-resistanct NSCLC
cells, as well as the metastasis in NSCLC patients.
Aurora-A amplification and overexpression have been
reported to be significantly associated with aneuploidy,
high tumor grade, increased invasiveness and poor prog-
nosis [13,29,30]. Due to dysregulation of the spindle
checkpoint, Aurora-A has been implicated in conferring
resistance to chemotherapy in cancer cells. As the under-
lying mechanism of Aurora-A involving in chemoresis-
tance, it remains complicated and varies in various types
of human cancers. Elevated Aurora-A expression confers
resistance to apoptosis induced by chemotherapeutic
agents [16,31,32]. Inhibition of Aurora-A in cells ex-
pressing mutant JAK2 abolishes the resistance to cis-
platin [33], and enhances cisplatin-induced cell death in
esophageal carcinoma cells [34,35]. It has been reported
that Aurora-A induces cisplatin chemoresistance by inhib-
ition of p53, leading to down-regulation of PTEN and acti-
vation of Akt in human ovarian cancer cells [36]. Some
studies show that Aurora-A promotes chemotherapeutic
Figure 6 (See legend on next page.)
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Figure 6 Inhibition of Aurora-A reverses migration ability of cisplatin-resistant cells. (A) A549 and A549/DDP cells were transfected with
negative control (NC) or Aurora-A siRNA for 48 h and subjected to western blotting. Cells transfected with siRNA were treated with or without
DDP (10 μM), and the cell migration ability was examined by wound healing assay. Images were captured at the time points as indicated.
(B) A549 and A549/DDP cells were treated with DDP at 0 (control) and 10 μM, in combination with or without VX-680 (5 nM) or MLN8237 (0.2 μM).
Then the cells were subjected to wound healing assay and relative wound closure quantified.
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knockdown lung cancer cells [37].
Chemoresistance has been reported to correlate closely
with metastasis in human cancer patients. Metastatic tu-
mors are invariably more resistant to the chemotherapy
compared to primary tumors as evidenced by the marked
decrease of chemotherapy response rate in metastatic set-
tings [38,39]. Moreover, recent studies have shown a link
between chemotherapy resistance and the EMT pheno-
type [40-42]. For example, resistance to cisplatin was
observed in cell lines undergoing EMT [43,44]. EMT is a
process by which epithelial cells undergo transition to a
mesenchymal phenotype, with increasing motility and in-
vasive capacity. EMT increased malignant potential and
reduced sensitivity to cisplatin and paclitaxel in NSCLC
cells. Therapeutic combinations using EMT-signaling in-
hibitors may be needed to circumvent the resistance of
some types of cancer to chemotherapy [45,46].
Previously, we found that Aurora-A promoted EMT
and invasion in nasopharyngeal carcinoma mediated by
mitogen-activated protein kinase (MAPK) phosphoryl-
ation [47], and increased laryngeal squamous cell carcin-
oma (LSCC) cell growth and migration mediated by
activation of Akt1 [17]. More recently, we further dem-
onstrated that Aurora-A overexpression enhanced breast
cancer cell migration by activating the cofilin-F-actin
pathway [18] and predicted an inferior prognosis of
triple negative breast cancer (TNBC) [48]. Combined
with our previous results, the presents study further sup-
port that contribution of Aurora-A overexpression to
the cisplatin resistance and the poor prognosis pattern
in NSCLC patients treated with cisplatin-based therapy
may be ascribed to the high proliferation- and metastasis-
promoting function of Aurora-A. Aurora-A may also
increase the risk of metastatic recurrence against chemo-
therapy, although this was not proven directly in our
current study due to difficulty in segregating the two func-
tions (chemoresistance and migration). The mechanism of
regulation of downstream factors by Aurora-A to clarify
this link and interaction will be important matters to be
addressed by future studies.
Conclusion
In summary, our data suggest that increased expression
of Aurora-A is related to cisplatin resistance and lymph-
atic metastasis in NSCLC and contributes to a poor
prognostic phenotype. Aurora-A could be a potentialcisplatin-resistance target in NSCLC, and inhibition of
Aurora-A kinase is a promising regimen to overcome
cisplatin resistance in NSCLC patients.
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